Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

Rodríguez-Sevilla, Juan José; Gañán-Gómez, Irene; Ma, Feiyang; Chien, Kelly; Rey, Mónica del; Loghavi, Sanam; Montalban-Bravo, Guillermo; Ademá, Vera; Wildeman, Bethany; Kanagal-Shamanna, Rashmi; Bazinet, Alexandre; Chifotides, Helen T.; Thongon, Natthakan; Calvo Gonzalo, Xavier; Hernández-Rivas, Jesús María; Díez-Campelo, María; Garcia-Manero, Guillermo; Colla, Simona

doi:http://dx.doi.org/10.1038/s41467-024-46424-3

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

Citation

Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, Chien K, Del Rey M, Loghavi S, et al. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun. 2024 Mar 18;15(1):2428. DOI: 10.1038/s41467-024-46424-3

Abstract

The molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be elucidated. Here, we show an expansion of MDS hematopoietic stem cells (HSCs) with a granulo-monocytic-biased transcriptional differentiation state in MDS patients who initially responded to venetoclax but eventually relapsed. While MDS HSCs in an undifferentiated cellular state are sensitive to venetoclax treatment, differentiation towards a granulo-monocytic-biased transcriptional state, through the acquisition or expansion of clones with STAG2 or RUNX1 mutations, affects HSCs' survival dependence from BCL2-mediated anti-apoptotic pathways to TNFα-induced pro-survival NF-κB signaling and drives resistance to venetoclax-mediated cytotoxicity. Our findings reveal how hematopoietic stem and progenitor cell (HSPC) can eventually overcome therapy-induced depletion and underscore the importance of using close molecular monitoring to prevent HSPC hierarchical change in MDS patients enrolled in clinical trials of venetoclax.